ADA and Miyoshi myopathy: A study of ADA testing of 55 R/R MM patients participating in LCAR-B38M treatment found that 34 (62%) were ADA positive, and the frequency of ADA in cyclophosphamide plus fludarabine group was lower than that in cyclophosphamide group, suggesting the choice of lymphodepleting regimen has an important influence on ADA generation.